213 related articles for article (PubMed ID: 16467500)
1. Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension.
Ferrari P; Ferrandi M; Valentini G; Bianchi G
Am J Physiol Regul Integr Comp Physiol; 2006 Mar; 290(3):R529-35. PubMed ID: 16467500
[TBL] [Abstract][Full Text] [Related]
2. Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach.
Ferrari P; Ferrandi M; Valentini G; Manunta P; Bianchi G
Med Hypotheses; 2007; 68(6):1307-14. PubMed ID: 17097240
[TBL] [Abstract][Full Text] [Related]
3. Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension.
Ferrari P
Biochim Biophys Acta; 2010 Dec; 1802(12):1254-8. PubMed ID: 20083196
[TBL] [Abstract][Full Text] [Related]
4. Ouabain-dependent signaling in caveolae as a novel therapeutic target for hypertension.
Ferrandi M; Molinari I; Bianchi G; Ferrari P
Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(8):15-8. PubMed ID: 17535730
[TBL] [Abstract][Full Text] [Related]
5. Ouabain antagonists as antihypertensive agents.
Ferrandi M; Barassi P; Molinari I; Torielli L; Tripodi G; Minotti E; Bianchi G; Ferrari P
Curr Pharm Des; 2005; 11(25):3301-5. PubMed ID: 16250857
[TBL] [Abstract][Full Text] [Related]
6. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies.
Ferrandi M; Molinari I; Torielli L; Padoani G; Salardi S; Rastaldi MP; Ferrari P; Bianchi G
Sci Transl Med; 2010 Nov; 2(59):59ra86. PubMed ID: 21106940
[TBL] [Abstract][Full Text] [Related]
7. A new antihypertensive agent that antagonizes the prohypertensive effect of endogenous ouabain and adducin.
Manunta P; Ferrandi M; Messaggio E; Ferrari P
Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):61-6. PubMed ID: 16529550
[TBL] [Abstract][Full Text] [Related]
8. Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain.
Ferrandi M; Molinari I; Rastaldi MP; Ferrari P; Bianchi G; Manunta P
J Pharmacol Exp Ther; 2014 Nov; 351(2):278-87. PubMed ID: 25187430
[TBL] [Abstract][Full Text] [Related]
9. Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin.
Staessen JA; Thijs L; Stolarz-Skrzypek K; Bacchieri A; Barton J; Espositi ED; de Leeuw PW; Dłużniewski M; Glorioso N; Januszewicz A; Manunta P; Milyagin V; Nikitin Y; Souček M; Lanzani C; Citterio L; Timio M; Tykarski A; Ferrari P; Valentini G; Kawecka-Jaszcz K; Bianchi G
Trials; 2011 Jan; 12():13. PubMed ID: 21235787
[TBL] [Abstract][Full Text] [Related]
10. PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension.
Ferrari P; Ferrandi M; Tripodi G; Torielli L; Padoani G; Minotti E; Melloni P; Bianchi G
J Pharmacol Exp Ther; 1999 Mar; 288(3):1074-83. PubMed ID: 10027844
[TBL] [Abstract][Full Text] [Related]
11. PST 2238: a new antihypertensive compound that modulates renal Na-K pump function without diuretic activity in Milan hypertensive rats.
Ferrandi M; Barassi P; Minotti E; Duzzi L; Molinari I; Bianchi G; Ferrari P
J Cardiovasc Pharmacol; 2002 Dec; 40(6):881-9. PubMed ID: 12451321
[TBL] [Abstract][Full Text] [Related]
12. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies.
Lanzani C; Citterio L; Glorioso N; Manunta P; Tripodi G; Salvi E; Carpini SD; Ferrandi M; Messaggio E; Staessen JA; Cusi D; Macciardi F; Argiolas G; Valentini G; Ferrari P; Bianchi G
Sci Transl Med; 2010 Nov; 2(59):59ra87. PubMed ID: 21106941
[TBL] [Abstract][Full Text] [Related]
13. PST 2238: a new antihypertensive compound that modulates the Na-K pump 'in vivo' and 'in vitro'.
Ferrari P; Ferrandi M; Torielli L; Tripodi G; Bianchi G
Hypertens Res; 2000 Sep; 23 Suppl():S15-9. PubMed ID: 11016814
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive compounds that modulate the Na-K pump.
Ferrari P; Ferrandi M; Torielli L; Barassi P; Tripodi G; Minotti E; Molinari I; Melloni P; Bianchi G
Ann N Y Acad Sci; 2003 Apr; 986():694-701. PubMed ID: 12763920
[TBL] [Abstract][Full Text] [Related]
15. OASIS-HT: design of a pharmacogenomic dose-finding study.
Staessen JA; Kuznetsova T; Acceto R; Bacchieri A; Brand E; Burnier M; Celis H; Citterio L; de Leeuw PW; Filipovský J; Fournier A; Kawecka-Jaszcz K; Manunta P; Nikitin Y; O'Brien ET; Redón J; Thijs L; Ferrari P; Valentini G; Bianchi G
Pharmacogenomics; 2005 Oct; 6(7):755-75. PubMed ID: 16207152
[TBL] [Abstract][Full Text] [Related]
16. Genetics of primary hypertension: the clinical impact of adducin polymorphisms.
Citterio L; Lanzani C; Manunta P; Bianchi G
Biochim Biophys Acta; 2010 Dec; 1802(12):1285-98. PubMed ID: 20382219
[TBL] [Abstract][Full Text] [Related]
17. PST2238: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain.
Ferrari P; Torielli L; Ferrandi M; Padoani G; Duzzi L; Florio M; Conti F; Melloni P; Vesci L; Corsico N; Bianchi G
J Pharmacol Exp Ther; 1998 Apr; 285(1):83-94. PubMed ID: 9535997
[TBL] [Abstract][Full Text] [Related]
18. Adducin and hypertension.
Staessen JA; Bianchi G
Pharmacogenomics; 2005 Oct; 6(7):665-9. PubMed ID: 16207143
[TBL] [Abstract][Full Text] [Related]
19. Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt hypertensive rats: the role of Na+K+-ATPase/ cSRC pathway.
Wenceslau CF; Rossoni LV
J Hypertens; 2014 Mar; 32(3):542-54. PubMed ID: 24309491
[TBL] [Abstract][Full Text] [Related]
20. Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238.
Ferrandi M; Molinari I; Barassi P; Minotti E; Bianchi G; Ferrari P
J Biol Chem; 2004 Aug; 279(32):33306-14. PubMed ID: 15161929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
